The story of Sildenafil presents a complex picture for investors. While the initial release generated massive gains, the end of its patent opened the avenue to generic alternatives, dramatically eroding sales. This https://bookmarkpressure.com/story21554226/sildenafil-and-pharma-a-volatile-bet